{"id":"imiquimod-5-topical-cream","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Local skin irritation (erythema, edema)"},{"rate":"20-40","effect":"Pruritus"},{"rate":"10-30","effect":"Erosion or ulceration"},{"rate":"5-15","effect":"Flu-like symptoms"},{"rate":"5-10","effect":"Lymphadenopathy"}]},"_chembl":{"chemblId":"CHEMBL1282","moleculeType":"Small molecule","molecularWeight":"240.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Imiquimod binds to TLR7 on immune cells, triggering the production of interferon-alpha and other pro-inflammatory cytokines. This activation enhances both innate and adaptive immune responses at the site of application, making it effective for treating viral infections and certain skin cancers by promoting immune-mediated clearance of abnormal cells.","oneSentence":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to enhance local antiviral and antitumor immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:13.741Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis"},{"name":"Basal cell carcinoma"},{"name":"Genital warts (external)"},{"name":"Superficial cutaneous lymphoma"}]},"trialDetails":[{"nctId":"NCT07210775","phase":"PHASE1, PHASE2","title":"Topical Imiquimod Treatment of Oral Dysplasia","status":"RECRUITING","sponsor":"University of Southern California","startDate":"2025-10-01","conditions":"Oral Dysplasia, Leukoplakia Oral, Leukoplakia","enrollment":20},{"nctId":"NCT05212246","phase":"PHASE3","title":"Basal Cell Carcinoma Chemoprevention Trial","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-05-01","conditions":"Basal Cell Carcinoma","enrollment":1630},{"nctId":"NCT07251413","phase":"PHASE1, PHASE2","title":"Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma","status":"RECRUITING","sponsor":"Instituto Oncológico Dr Rosell","startDate":"2025-10-22","conditions":"Cutaneous Basal Cell Carcinoma","enrollment":18},{"nctId":"NCT04808245","phase":"PHASE1","title":"A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"German Cancer Research Center","startDate":"2023-02-15","conditions":"Newly Diagnosed H3-mutated Glioma","enrollment":15},{"nctId":"NCT03370406","phase":"PHASE1","title":"Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC","status":"RECRUITING","sponsor":"Melissa Pugliano-Mauro","startDate":"2018-08-03","conditions":"Carcinoma, Squamous Cell","enrollment":30},{"nctId":"NCT06840470","phase":"PHASE4","title":"Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-03-11","conditions":"Sebaceous Hyperplasia","enrollment":40},{"nctId":"NCT02078648","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Stemline Therapeutics, Inc.","startDate":"2014-05","conditions":"Adult Brain Glioblastoma, Glioblastoma Multiforme","enrollment":74},{"nctId":"NCT04883645","phase":"EARLY_PHASE1","title":"Neoadjuvant Imiquimod Immunotherapy for Oral Cancer","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2022-04-28","conditions":"Oral Squamous Cell Carcinoma","enrollment":16},{"nctId":"NCT03943407","phase":"NA","title":"Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch","status":"WITHDRAWN","sponsor":"Aalborg University","startDate":"2019-11-01","conditions":"Itch","enrollment":""},{"nctId":"NCT02394132","phase":"PHASE3","title":"Radiotherapy or Imiquimod in Complex Lentigo Maligna","status":"COMPLETED","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2015-08-31","conditions":"Lentigo Maligna","enrollment":126},{"nctId":"NCT05838599","phase":"EARLY_PHASE1","title":"Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2023-07-24","conditions":"Mycosis Fungoides","enrollment":25},{"nctId":"NCT00314756","phase":"PHASE4","title":"Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2005-03","conditions":"Basal Cell Carcinoma","enrollment":15},{"nctId":"NCT05468606","phase":"EARLY_PHASE1","title":"Coadministration of GA2 Sporozoites With Adjuvants","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2023-02-03","conditions":"Malaria,Falciparum","enrollment":45},{"nctId":"NCT01720407","phase":"PHASE3","title":"Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2012-12","conditions":"Lentigo Maligna Melanoma (Head or Neck)","enrollment":259},{"nctId":"NCT00585247","phase":"NA","title":"Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2006-11","conditions":"Port Wine Stain","enrollment":27},{"nctId":"NCT00142454","phase":"PHASE1","title":"NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2005-08-24","conditions":"Malignant Melanoma","enrollment":9},{"nctId":"NCT01808820","phase":"PHASE1","title":"Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma","status":"COMPLETED","sponsor":"Macarena De La Fuente, MD","startDate":"2013-08-21","conditions":"Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma","enrollment":20},{"nctId":"NCT04083157","phase":"PHASE2, PHASE3","title":"Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-08-12","conditions":"Inflammatory Bowel Diseases, Hepatitis B","enrollment":104},{"nctId":"NCT05314127","phase":"PHASE2","title":"Efficacy of Tazarotene in Treatment of Verruca Plana","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2022-04-15","conditions":"Warts Flat","enrollment":80},{"nctId":"NCT05315024","phase":"NA","title":"Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-04-30","conditions":"Influenza","enrollment":72},{"nctId":"NCT04279535","phase":"EARLY_PHASE1","title":"Topical Vitamin C for Treatment of Basal Cell Cancer","status":"COMPLETED","sponsor":"Center for Biomedical Research, Inc.","startDate":"2018-03-01","conditions":"Basal Cell Carcinoma","enrollment":25},{"nctId":"NCT03982004","phase":"PHASE1","title":"Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-09-14","conditions":"Metastatic Breast Cancer","enrollment":1},{"nctId":"NCT04859361","phase":"NA","title":"Comparison of Treatment of Cervical Intraepithelial Lesions With Imiquimod or LLETZ","status":"UNKNOWN","sponsor":"University Medical Centre Maribor","startDate":"2018-11-20","conditions":"Intraepithelial Neoplasia, Cervical","enrollment":104},{"nctId":"NCT04143451","phase":"PHASE3","title":"Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2019-10-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT03233412","phase":"PHASE2","title":"Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions","status":"COMPLETED","sponsor":"Barretos Cancer Hospital","startDate":"2018-01-01","conditions":"High Grade Intraepithelial Neoplasia, Cervix Cancer","enrollment":90},{"nctId":"NCT02482428","phase":"PHASE2","title":"Efficacy and Tolerability of Topical LFX453 for External Genital Warts","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05-12","conditions":"External Genital Warts","enrollment":88},{"nctId":"NCT03760250","phase":"PHASE2","title":"Imiquimod for Preventing Keloid Recurrence","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2019-02-05","conditions":"Keloid","enrollment":6},{"nctId":"NCT03289260","phase":"PHASE3","title":"Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial","status":"UNKNOWN","sponsor":"Medical University Innsbruck","startDate":"2021-11-15","conditions":"Anogenital Human Papillomavirus Infection, Condyloma Anal","enrollment":200},{"nctId":"NCT00948428","phase":"PHASE3","title":"Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2008-05","conditions":"Actinic Keratoses","enrollment":462},{"nctId":"NCT02293707","phase":"PHASE2","title":"A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Laboratoires Leurquin Mediolanum","startDate":"2014-11","conditions":"Prostate Cancer","enrollment":99},{"nctId":"NCT04072900","phase":"PHASE1","title":"A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2020-04-21","conditions":"Melanoma (Skin)","enrollment":30},{"nctId":"NCT02224599","phase":"PHASE1, PHASE2","title":"Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies","status":"TERMINATED","sponsor":"Kiromic BioPharma Inc.","startDate":"2017-07-28","conditions":"Progressive Solid Malignancies, Refractory Solid Malignancies, Cancer","enrollment":3},{"nctId":"NCT03472976","phase":"PHASE1","title":"H5N1 With or Without Topical Aldara in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-06-13","conditions":"Avian Influenza, Influenza Immunisation","enrollment":50},{"nctId":"NCT03901690","phase":"PHASE3","title":"Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study","status":"UNKNOWN","sponsor":"Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri","startDate":"2019-08-27","conditions":"Genital Wart Virus Infection","enrollment":102},{"nctId":"NCT02385188","phase":"PHASE3","title":"Topical 5% Imiquimod Cream for Vulvar Paget's Disease","status":"COMPLETED","sponsor":"University Medical Center Nijmegen","startDate":"2015-05","conditions":"Paget Disease, Extramammary","enrollment":25},{"nctId":"NCT02621112","phase":"PHASE2, PHASE3","title":"HBV Vaccine in Renal Failure Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2016-01","conditions":"Renal Failure","enrollment":94},{"nctId":"NCT02329171","phase":"PHASE3","title":"Imiquimod Treatment of CIN Lesions","status":"TERMINATED","sponsor":"Maastricht University Medical Center","startDate":"2014-12","conditions":"Cervical Intraepithelial Neoplasia","enrollment":9},{"nctId":"NCT00638651","phase":"PHASE1","title":"Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal","status":"COMPLETED","sponsor":"University of Miami","startDate":"2008-02","conditions":"Healthy","enrollment":3},{"nctId":"NCT02960815","phase":"PHASE2","title":"Imiquimod and Influenza Vaccine for Immunocompromised Patients","status":"COMPLETED","sponsor":"University of Lausanne Hospitals","startDate":"2016-11","conditions":"Influenza Vaccine","enrollment":70},{"nctId":"NCT01538901","phase":"PHASE4","title":"Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2012-09","conditions":"Actinic Keratoses","enrollment":10},{"nctId":"NCT01059110","phase":"PHASE4","title":"Comparison of Five Treatments in Patients With Plantar Warts","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-02","conditions":"Plantar Warts","enrollment":358},{"nctId":"NCT00865644","phase":"PHASE1","title":"Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-03","conditions":"Neurofibromatosis Type 1, Cutaneous Neurofibromas","enrollment":11},{"nctId":"NCT01264731","phase":"PHASE1","title":"Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2011-01","conditions":"Melanoma","enrollment":4},{"nctId":"NCT00774787","phase":"PHASE4","title":"Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses","status":"COMPLETED","sponsor":"Rigel Dermatology","startDate":"2008-10","conditions":"Actinic Keratoses","enrollment":27},{"nctId":"NCT00470392","phase":"NA","title":"Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2007-05","conditions":"Psoriasis","enrollment":9},{"nctId":"NCT00899574","phase":"PHASE2","title":"Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2009-05","conditions":"Breast Cancer, Breast Neoplasms","enrollment":10},{"nctId":"NCT00066872","phase":"PHASE3","title":"Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer","status":"COMPLETED","sponsor":"Queen's Medical Center","startDate":"2002-10","conditions":"Non-melanomatous Skin Cancer","enrollment":500},{"nctId":"NCT01935310","phase":"NA","title":"Photoaging Treatment With Imiquimod","status":"COMPLETED","sponsor":"CES University","startDate":"2010-07","conditions":"Photoaging","enrollment":17},{"nctId":"NCT00147771","phase":"PHASE3","title":"Imiquimod in Children With Plaque Morphea","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2005-09","conditions":"Scleroderma, Localized","enrollment":10},{"nctId":"NCT00707174","phase":"NA","title":"Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna","status":"COMPLETED","sponsor":"University of Utah","startDate":"2005-03","conditions":"Cancer, Lentigo Maligna","enrollment":90},{"nctId":"NCT01161888","phase":"PHASE4","title":"Effect of Topical Imiquimod on Lentigo Maligna","status":"COMPLETED","sponsor":"Jerry Marsden","startDate":"2010-06","conditions":"Lentigo Maligna","enrollment":30},{"nctId":"NCT00204555","phase":"PHASE4","title":"Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2002-01","conditions":"Carcinoma, Basal Cell","enrollment":100},{"nctId":"NCT01380314","phase":"PHASE2","title":"Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis","status":"COMPLETED","sponsor":"Foundation Fader","startDate":"2008-03","conditions":"Cutaneous Leishmaniasis","enrollment":60},{"nctId":"NCT00110682","phase":"PHASE4","title":"Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses","status":"COMPLETED","sponsor":"Derm Research @ 888 Inc.","startDate":"2005-04","conditions":"Keratosis, Actinic Keratosis","enrollment":60},{"nctId":"NCT00601016","phase":"PHASE2","title":"A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy","status":"COMPLETED","sponsor":"St. Justine's Hospital","startDate":"2005-03","conditions":"Hemangioma, Capillary","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aldara"],"phase":"marketed","status":"active","brandName":"Imiquimod 5% Topical Cream","genericName":"Imiquimod 5% Topical Cream","companyName":"University of Michigan","companyId":"university-of-michigan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to enhance local antiviral and antitumor immunity. Used for Actinic keratosis, Basal cell carcinoma, Genital warts (external).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}